BGBIO Bergenbio ASA

BerGenBio (BGBIO): Progressing towards key inflection points

Edison Investment Research Limited
BerGenBio (BGBIO): Progressing towards key inflection points

17-Dec-2020 / 08:00 GMT/BST

 

London, UK, 17 December 2020

BerGenBio (BGBIO): Progressing towards key inflection points

BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020. Following these data, we anticipate a registrational Phase III study of bemcentinib plus low-dose cytarabine (LDAC) in relapsed elderly AML patients to start in 2021. We still forecast the NDA submission for this indication in 2023 (FDA fast-track has been granted). Bemcentinib is an oral, first-in-class, highly selective AXL tyrosine kinase inhibitor in Phase II development for a range of cancers and could be the first selective AXL inhibitor to market. Data from the Phase II study in second-line NSCLC in combination with Keytruda are expected at WCLC (for details see our initiation report, Bemcentinib leading the AXL charge). We value BerGenBio at NOK59.1 per share.

 

We continue to value BerGenBio at NOK5.16bn or NOK59.1 per share based on a risk-adjusted NPV analysis. Our forecasts remain unchanged. The key drivers are bemcentinib in second-line NSCLC (peak sales $1.2bn, NOK40.7/share) and AML (peak sales $588m, NOK13.3/share) plus COVID-19 opportunity (NOK5.9/share).  


to view the full report.

 

to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the .

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Dr Susie Jana, +44 (0)20 3077 5700

Dr Jonas Peciulis, +44 (0)20 3077 5728

Dr John Priestner, +44 (0)20 3077 5700

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube       


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1155863  17-Dec-2020 

fncls.ssp?fn=show_t_gif&application_id=1155863&application_name=news&site_id=research_pool
EN
17/12/2020

Underlying

BGBIOBergenbio ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bergenbio ASA

Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (No_rec, TP: NOK) - Decision to end BGBC016 trial – recommen...

BerGenBio announced yesterday that it has decided to discontinue its 1L STK11m NSCLC trial due to the weak preliminary results. We already believed the value of the data would be limited, but this is a significant setback for the company. BerGenBio said that it is entering a new phase, in which strategic alternatives will be explored. As a result of the trial discontinuation, the company’s financial situation, and limited available information on the potential alternatives being explored, we hav...

02/26/25 February 26, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK5.00) - Decision to end BGBC016 trial

BerGenBio announced tonight that it has decided to discontinue its 1L STK11m NSCLC trial due to preliminary results not being strong enough. We already believed the value of the data would be limited, and this is a significant setback for the company. The company said that it is now entering a new phase in which strategic alternatives will be explored.

02/25/25 February 25, 2025 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK5.00) - Q2 report

BerGenBio said that its BGBC016 trial is progressing as planned, with all sites in the phase IIa part activated. It expects a phase IIa interim analysis at end-2024. We reiterate our SELL and NOK5 target price.

08/26/24 August 26, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK0.05) - Q1 report

While the Q1 report contained no large surprises, the company announced earlier this week a clinical collaboration with UT Health San Antonio and Sobi to evaluate bemcentinib in combination with Sobi’s pacritinib in patients with advanced lung adenocarcinoma. We reiterate our SELL and NOK0.05 target price on our concerns about the company’s ability to generate sufficient investor interest during its financial runway and ahead of the next need for financing.

05/30/24 May 30, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
BGBIO BERGENBIO ASA

BerGenBio (Sell, TP: NOK0.05) - Our concerns remain

While opex fell sharply in 2023 and YOY in Q4, and management maintained the timeline for its BGBC016 study, we remain concerned about a lack of major share-price catalysts ahead of the next needed capital raise. We reiterate our SELL and NOK0.05 target price.

02/25/24 February 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch